- Home
- LVTX vs TURN Comparison
LVTX vs TURN Comparison
Compare LVTX & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- TURN
- Stock Information
- Founded
- LVTX 2016
- TURN 1981
- Country
- LVTX Netherlands
- TURN United States
- Employees
- LVTX N/A
- TURN N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- TURN Finance/Investors Services
- Sector
- LVTX Health Care
- TURN Finance
- Exchange
- LVTX Nasdaq
- TURN Nasdaq
- Market Cap
- LVTX 33.9M
- TURN 39.9M
- IPO Year
- LVTX 2021
- TURN N/A
- Fundamental
- Price
- LVTX $1.31
- TURN $3.97
- Analyst Decision
- LVTX Hold
- TURN
- Analyst Count
- LVTX 3
- TURN 0
- Target Price
- LVTX $1.75
- TURN N/A
- AVG Volume (30 Days)
- LVTX 39.1K
- TURN 16.9K
- Earning Date
- LVTX 08-19-2025
- TURN 08-18-2025
- Dividend Yield
- LVTX N/A
- TURN N/A
- EPS Growth
- LVTX N/A
- TURN N/A
- EPS
- LVTX N/A
- TURN N/A
- Revenue
- LVTX $4,990,000.00
- TURN $194,813.00
- Revenue This Year
- LVTX N/A
- TURN N/A
- Revenue Next Year
- LVTX N/A
- TURN N/A
- P/E Ratio
- LVTX N/A
- TURN N/A
- Revenue Growth
- LVTX N/A
- TURN 254.25
- 52 Week Low
- LVTX $0.85
- TURN $3.12
- 52 Week High
- LVTX $2.39
- TURN $4.25
- Technical
- Relative Strength Index (RSI)
- LVTX 51.02
- TURN 46.15
- Support Level
- LVTX $1.28
- TURN $3.88
- Resistance Level
- LVTX $1.40
- TURN $4.00
- Average True Range (ATR)
- LVTX 0.05
- TURN 0.09
- MACD
- LVTX -0.00
- TURN -0.01
- Stochastic Oscillator
- LVTX 52.63
- TURN 45.45
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.